WallStreetZenWallStreetZen

NASDAQ: AKBA
Akebia Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

AKBA past revenue growth

How has AKBA's revenue growth performed historically?
Company
21.55%
Industry
69.21%
Market
13.96%
AKBA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AKBA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AKBA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AKBA earnings and revenue history

Current Revenue
$271.0M
Current Earnings
-$56.4M
Current Profit Margin
-20.8%

AKBA Return on Equity

Current Company
-316.9%
Current Industry
-17.9%
Current Market
30.8%
AKBA's Return on Equity (-316.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when AKBA announces earnings.

AKBA Return on Assets

Current Company
-14.2%
Current Industry
1%
AKBA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AKBA Return on Capital Employed

Current Company
-22.78%
Current Industry
14.2%
AKBA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AKBA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AKBA$271.03M-$8.93M-$56.36M+5.61%N/A
THRDN/AN/AN/AN/AN/A
CARM$43.24M-$43.99M-$43.73M+66.78%N/A
MOLN$22.32M-$52.53M-$56.24M-88.94%N/A
RANI$0.00-$37.30M-$41.08M-100.00%N/A
View Top Biotech Stocks

Akebia Therapeutics Earnings & Revenue FAQ

What were AKBA's earnings last quarter?

On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q1 2023 earnings per share (EPS) of -$0.14, up 60% year over year. Total Akebia Therapeutics earnings for the quarter were -$26.22 million. In the same quarter last year, Akebia Therapeutics's earnings per share (EPS) was -$0.35.

If you're new to stock investing, here's how to buy Akebia Therapeutics stock.

What was AKBA's earnings growth in the past year?

As of Q2 2023, Akebia Therapeutics's earnings has grown year over year. Akebia Therapeutics's earnings in the past year totalled -$56.36 million.

What was AKBA's revenue last quarter?

On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q1 2023 revenue of $40.13 million up 34.96% year over year. In the same quarter last year, Akebia Therapeutics's revenue was $61.70 million.

What was AKBA's revenue growth in the past year?

As of Q2 2023, Akebia Therapeutics's revenue has grown 21.55% year over year. This is 47.66 percentage points lower than the US Biotechnology industry revenue growth rate of 69.21%. Akebia Therapeutics's revenue in the past year totalled $271.03 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.